Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 13/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30446215 | 0.87 | ATF4 (0.79) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20974142 | 0.86 | ATF4 (1.00) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20973090 | 0.85 | ATF4 (0.81) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL19555682 | 0.84 | ATF4 (0.70) | ATF4MEN1KMT2ANPC1 | |
| SCHEMBL19555369 | 0.84 | ATF4 (0.83) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20721974 | 0.83 | ATF4 (0.64) | ATF4 | |
| SCHEMBL20722103 | 0.83 | ATF4 (0.77) | ATF4MEN1KMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL20610394 | 0.83 | ATF4 (0.81) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20582511 | 0.82 | ATF4 (0.84) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21618354 | 0.82 | ATF4 (0.79) | ATF4MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240059662-A1 | SOLID FORMS OF A COMPOUND | DENALI THERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-4263488-A1 | SOLID FORMS OF A COMPOUND | Denali Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116710427-A | Solid forms of the compounds | 戴纳立制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022133236-A1 | SOLID FORMS OF A COMPOUND | DENALI THERAPEUTICS INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ATF4 187/4885MEN1 3106/4885KMT2A 3643/4885 |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ATF4 187/4885MEN1 3106/4885KMT2A 3643/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | ATF4 183/4885MEN1 3690/4885KMT2A 4120/4885 |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | ATF4 187/4885MEN1 3106/4885KMT2A 3643/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | ATF4 81/4885MEN1 2284/4885KMT2A 3980/4885 |
| US-20240059662-A1 | SOLID FORMS OF A COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1, ACACA | ATF4 1093/4885MEN1 668/4885KMT2A 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.